Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| XBI - Spdr S&P Biotech ETF | 9.10% | Reduce −1.0% | 397,505 | $90.06 | $36M | −4,000 | −$4M |
| STXS - Stereotaxis | 7.93% | Hold | 13,680,554 | $2.28 | $31M | — | — |
| RVMD - Revolution Medicines | 7.02% | Add +21.9% | 631,176 | $43.74 | $28M | +113,182 | +$4M |
| ATRC - Atricure | 4.98% | Hold | 641,673 | $30.56 | $20M | — | — |
| Merus | 4.83% | Add +9.5% | 451,804 | $42.05 | $19M | +39,231 | −$2M |
| CYTK - Cytokinetics | 4.76% | Hold | 398,100 | $47.04 | $19M | — | — |
| ASND - Ascendis Pharma A/S | 3.62% | Add +15.4% | 103,355 | $137.67 | $14M | +13,783 | +$855K |
| AXGN - Axogen | 3.55% | Reduce −9.5% | 846,882 | $16.48 | $14M | −89,012 | +$835K |
| NDAQ - Ishares Nasdaq Biotech Indx | 3.44% | Hold | 102,500 | $132.21 | $14M | — | — |
| Blueprint Medicines | 3.32% | Add +23.0% | 149,763 | $87.22 | $13M | +28,000 | +$2M |
| IDYA - Ideaya Biosciences | 3.26% | Add +5.8% | 498,827 | $25.70 | $13M | +27,417 | −$2M |
| XENE - Xenon Pharmaceuticals | 2.73% | Hold | 273,739 | $39.20 | $11M | — | — |
| NBIX - Neurocrine Biosciences | 2.48% | Add +2.9% | 71,615 | $136.50 | $10M | +2,000 | +$2M |
| DAWNGBX — | 2.36% | Reduce −2.5% | 731,363 | $12.67 | $9M | −19,000 | −$1M |
| BHVN - Biohaven | 2.09% | Add +17.7% | 220,235 | $37.35 | $8M | +33,105 | −$1M |
| TNDM - Tandem Diabetes Care | 2.04% | Add +9.3% | 223,208 | $36.02 | $8M | +19,000 | −$621K |
| SNDX - Syndax Pharmaceuticals | 1.82% | Add +2.9% | 542,002 | $13.22 | $7M | +15,300 | −$3M |
| Kalvista Pharmaceuticals | 1.75% | Add +12.2% | 811,678 | $8.47 | $7M | +88,000 | −$2M |
| URGN - Urogen Pharma | 1.33% | Add +7.3% | 492,515 | $10.65 | $5M | +33,600 | −$583K |
| DXCM - Dexcom | 1.30% | Hold | 65,552 | $77.77 | $5M | — | — |
| BCRX - Biocryst Pharmaceuticals | 1.27% | Hold | 667,000 | $7.52 | $5M | — | — |
| EWTX - Edgewise Therapeutics | 1.27% | Reduce −17.9% | 187,140 | $26.70 | $5M | −40,766 | −$1M |
| TELA - Tela Bio | 1.11% | New | 1,441,029 | $3.02 | $4M | +1,441,029 | +$4M |
| PRQR - Proqr Therapeutics | 1.06% | Add +73.1% | 1,567,561 | $2.65 | $4M | +661,979 | +$3M |
| KURA - Kura Oncology | 0.99% | Add +9.8% | 448,368 | $8.71 | $4M | +40,000 | −$4M |
| RCUS - Arcus Biosciences | 0.96% | Reduce −1.0% | 254,217 | $14.89 | $4M | −2,500 | −$140K |
| LKFT - Galapagos | 0.91% | Hold | 130,175 | $27.50 | $4M | — | — |
| ALKS - Alkermes | 0.88% | Hold | 120,700 | $28.76 | $3M | — | — |
| PODD - Insulet | 0.82% | Reduce −22.0% | 12,400 | $261.07 | $3M | −3,500 | −$463K |
| CATBUSD - Astria Therapeutics | 0.68% | Add +17.9% | 299,775 | $8.94 | $3M | +45,610 | −$118K |
| IMVT - Immunovant | 0.68% | Add +107.7% | 107,996 | $24.77 | $3M | +56,000 | +$1M |
| ALLO - Allogene Therapeutics | 0.67% | Add +18.1% | 1,240,118 | $2.13 | $3M | +190,000 | −$299K |
| VKTX - Viking Therapeutics | 0.66% | Reduce −48.6% | 64,516 | $40.24 | $3M | −61,100 | −$5M |
| LXEO - Lexeo Therapeutics | 0.66% | Add +56.9% | 393,083 | $6.58 | $3M | +142,500 | +$321K |
| ARAY - Accuray | 0.62% | Hold | 1,222,358 | $1.98 | $2M | — | — |
| Keros Therapeutics | 0.52% | Add +76.7% | 130,316 | $15.83 | $2M | +56,562 | −$2M |
| INGN - Inogen | 0.49% | Hold | 208,790 | $9.17 | $2M | — | — |
| STOK - Stoke Therapeutics | 0.48% | Reduce −17.5% | 171,097 | $11.03 | $2M | −36,330 | −$662K |
| BCAX - Bicara Therapeutics | 0.47% | New | 105,500 | $17.42 | $2M | +105,500 | +$2M |
| BWAY - Brainsway | 0.46% | Reduce −23.1% | 193,208 | $9.43 | $2M | −58,138 | −$500K |
| MLYS - Mineralys Therapeutics | 0.46% | Hold | 146,500 | $12.31 | $2M | — | — |
| Immatics | 0.44% | Add +69.0% | 245,000 | $7.11 | $2M | +100,000 | +$88K |
| ALEC - Alector | 0.44% | Hold | 912,928 | $1.89 | $2M | — | — |
| IPSC - Century Therapeutics | 0.44% | Hold | 1,704,232 | $1.01 | $2M | — | — |
| BCYC - Bicycle Therapeutics | 0.43% | Reduce −1.1% | 120,799 | $14.00 | $2M | −1,401 | −$1M |
| Iteos Therapeutics | 0.37% | Add +16.6% | 188,347 | $7.68 | $1M | +26,763 | −$203K |
| LRMR - Larimar Therapeutics | 0.37% | Reduce −24.9% | 371,434 | $3.87 | $1M | −122,840 | −$2M |
| Regulus Therapeutics | 0.35% | Reduce −2.2% | 875,200 | $1.58 | $1M | −20,000 | −$23K |
| AUTL - Autolus Therapeutics | 0.35% | Add +20.5% | 586,667 | $2.35 | $1M | +100,000 | −$388K |
| Gossamer Bio | 0.32% | Reduce −0.7% | 1,409,262 | $0.9046 | $1M | −10,000 | −$125K |
| 2seventy Bio | 0.32% | Reduce −31.9% | 429,252 | $2.94 | $1M | −200,777 | −$2M |
| Holding | 0.32% | Add +85.9% | 2,511,374 | $0.5025 | $1M | +1,160,666 | +$39K |
| NGNE - Neurogene | 0.30% | Add +562.4% | 51,500 | $22.86 | $1M | +43,725 | +$851K |
| Mediwound | 0.29% | Hold | 64,479 | $17.80 | $1M | — | — |
| ALGN - Align Technology | 0.29% | New | 5,500 | $208.51 | $1M | +5,500 | +$1M |
| BNTX - Biontech Se | 0.25% | Hold | 8,500 | $113.95 | $969K | — | — |
| GPCR - Structure Therapeutics | 0.24% | Add +4.4% | 35,500 | $27.12 | $963K | +1,500 | −$530K |
| SPRY - Ars Pharmaceuticals | 0.24% | Reduce −40.1% | 88,790 | $10.55 | $937K | −59,504 | −$1M |
| CMPS - Compass Pathways | 0.23% | Hold | 243,210 | $3.78 | $919K | — | — |
| TSHA - Taysha Gene Therapies | 0.23% | New | 522,500 | $1.73 | $904K | +522,500 | +$904K |
| Polypid | 0.23% | Reduce −5.6% | 291,273 | $3.04 | $885K | −17,224 | −$176K |
| FHTX - Foghorn Therapeutics | 0.22% | Add +395.7% | 186,717 | $4.72 | $881K | +149,053 | +$531K |
| PVLA - Palvella Therapeutics | 0.22% | New | 71,452 | $12.00 | $857K | +71,452 | +$857K |
| Sutro Biopharma | 0.20% | Add +32.6% | 437,079 | $1.84 | $804K | +107,500 | −$336K |
| CNTA - Centessa Pharmaceuticals | 0.20% | Reduce −60.6% | 47,453 | $16.75 | $795K | −72,898 | −$1M |
| VIR - Vir Biotechnology | 0.19% | New | 100,000 | $7.34 | $734K | +100,000 | +$734K |
| Compugen | 0.17% | Hold | 447,202 | $1.53 | $684K | — | — |
| ACRV - Acrivon Therapeutics | 0.17% | Hold | 112,414 | $6.02 | $677K | — | — |
| Sage Therapeutics | 0.15% | Hold | 108,200 | $5.43 | $588K | — | — |
| Adicet Bio | 0.15% | Hold | 600,000 | $0.9620 | $577K | — | — |
| Masimo | 0.13% | Hold | 3,000 | $165.30 | $496K | — | — |
| AQST - Aquestive Therapeutics | 0.11% | Reduce −78.5% | 127,000 | $3.56 | $452K | −462,561 | −$2M |
| APRE - Aprea Therapeutics | 0.11% | Hold | 137,174 | $3.29 | $451K | — | — |
| ADCT - Adc Therapeutics SA | 0.11% | Add +9.8% | 224,081 | $1.99 | $446K | +20,000 | −$197K |
| CATX - Perspective Therapeutics | 0.11% | Reduce −43.5% | 130,169 | $3.19 | $415K | −100,153 | −$3M |
| BDTX — | 0.08% | Add +12.0% | 140,000 | $2.14 | $300K | +15,000 | −$244K |
| Biomx | 0.07% | Hold | 401,136 | $0.7301 | $293K | — | — |
| Acelyrin | 0.07% | Reduce −85.4% | 87,989 | $3.14 | $276K | −514,905 | −$3M |
| CMPX - Compass Therapeutics | 0.06% | Add +35.5% | 158,394 | $1.45 | $230K | +41,512 | +$15K |
| Nevro | 0.04% | Hold | 38,000 | $3.72 | $141K | — | — |
| Spero Therapeutics | 0.03% | Hold | 125,000 | $1.03 | $129K | — | — |
Showing top 50 of 81 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2024 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Nyxoah S A | 0.24% | Exit | 0 | $9.55 | $1M | −108,108 | −$1M |
| GRAL - Grail | 0.16% | Exit | 0 | $13.75 | $671K | −48,800 | −$671K |
| Tourmaline Bio | 0.12% | Exit | 0 | $25.69 | $491K | −19,110 | −$491K |
| VSTM - Verastem | 0.09% | Exit | 0 | $2.99 | $382K | −127,700 | −$382K |
| Adaptimmune Therapeutics | 0.08% | Exit | 0 | $0.9500 | $324K | −341,064 | −$324K |
| ANRO - Alto Neuroscience | 0.07% | Exit | 0 | $11.42 | $306K | −26,786 | −$306K |
| Neuronetics | 0.06% | Exit | 0 | $0.7586 | $238K | −313,717 | −$238K |
| Karyopharm Therapeutics | 0.04% | Exit | 0 | $0.8304 | $160K | −192,678 | −$160K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2